Skip to content

Abstract 10867: CXCR3 Blockade Uncouples Immunotherapy-Induced Myocarditis from Anti-Tumor Immunity Through Oxygen-Dependent mTORC1/HIF1α Metabolic Adaptation

Nov 2026 · Circulation · 0 citations

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can cause ICI myocarditis (ICIM), a potentially fatal complication driven by aberrant CD8 + T-cell responses. Current therapies reduce cardiac inflammation but may compromise anti-tumor immunity. We observed that CXCR3 inhibition protects against ICIM while enhancing anti-tumor efficacy, but the underlying mechanism remains unclear. Hypothesis: We hypothesized that local oxygen tension determines how CXCR3 regulates CD8 + T-cell metabolism and effector function, thereby differentially modulating cardiac versus tumor immunity during ICI therapy. Methods: Melanoma-bearing mice treated with anti-PD-1 and anti-CTLA-4 antibodies were received vehicle, dexamethasone, or the CXCR3 antagonist ACT-777991 . Cardiac injury was assessed by histopathology, troponin I, and immune-cell infiltration. scRNA-seq was performed on heart, tumor, and blood samples. Tumor and cardiac oxygen status was evaluated using pimonidazole staining. Mechanistic studies were performed using WT and Cxcr3 -/- CD8 + T cells cultured under normoxic (21%) or hypoxic (3%) conditions. Metabolic signaling, glycolysis, oxidative phosphorylation,and IFNγ production were assessed by WB, qPCR, Seahorse analysis, and flow cytometry. Results: ACT-777991 significantly reduced ICIM and serum troponin I levels while enhancing anti-tumor efficacy compared with ICI-treated controls ( Fig. 1A - F ). Flow cytometry showed reduced cardiac CD8 + and CXCR3 + CD8 + T cells without impairing tumor accumulation ( Fig. 1G - H ). scRNA-seq revealed distinct metabolic programs between cardiac and tumor Cxcr3 hi CD8 + T cells ( Fig. 1I - N ). Tumor Cxcr3 hi CD8 + T cells exhibited enrichment of hypoxia, glycolysis, mTORC1 signaling, and IFNγ response pathways relative to cardiac counterparts. ACT-777991 suppressed glycolysis and IFNγ in cardiac Cxcr3 hi CD8 + T cells but enhanced these in tumor Cxcr3 hi Tpex cells. Pimonidazole staining confirmed lower oxygen levels in tumors than in cardiac tissue ( Fig. 2A ). Mechanistically, under normoxia, Cxcr3 -/- reduced mTORC1, glycolytic genes, and IFNγ expression ( Fig. 2B - H ). In contrast, under hypoxia, Cxcr3 -/- reduced mTORC1 but with reduced p-PHD2 and enhanced HIF1α-associated glycolysis, ECAR, and IFNγ. mTORC1 inhibition mimicked CXCR3 blockade in an oxygen-dependent manner, supporting mTORC1 as a downstream mediator of CXCR3 signaling ( Fig. 2I ). Conclusions: CXCR3 blockade uncouples cardiac toxicity from anti-tumor immunity during ICI therapy through oxygen-dependent metabolic adaptation of CD8 + T cells. Oxygen-rich cardiac environments favor CXCR3-mTORC1 signaling, whereas hypoxic tumors permit HIF1α-dependent metabolic compensation following CXCR3 inhibition. These findings identify an oxygen-dependent CXCR3-mTORC1/HIF1α axis for safer cancer immunotherapy.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.